Based in Waltham, Massachusetts, with research facilities in Kansas City, Missouri, Proteon Therapeutics Inc. has reportedly drawn a new $15.2-million financing round. The company’s lead product, PRT-201, is in a Phase 2 clinical study; the drug is aimed at helping chronic kidney disease patients “undergoing surgery for arteriovenous fistula creation in preparation for hemodialysis,” according to the company’s Website.

U.S. Securities and Exchange Commission records apparently show that the biopharmaceutical’s latest round was backed by 19 firms, which were not listed by name, in an exchange of equity and options. According to a news source, previous investors include Bessemer Venture Partners, Devon Park Bioventures, MPM Bio IV NVS Strategic Fund LP, Vectis Healthcare & Life Sciences Fund, TVM Capital, Skyline Ventures, Prism VentureWorks, Intersouth Partners, and several “angel” investors. See Mass High Tech, August 12, 2011.